Page 35 - TD-4-3

Tumor Discovery Immunomodulatory effects of CDK4/6 inhibitors

inhibition in cancer: Beyond cell cycle arrest. Trends Cell cancer. Transl Lung Cancer Res. 2024;13(5):1032-1046.
Biol. 2018;28(11):911-925.
doi: 10.21037/tlcr-24-33
doi: 10.1016/j.tcb.2018.07.002
23. Li W, Guo F, Zeng R, et al. CDK4/6 alters TBK1
12. Hendrychova D, Jorda R, Krystof V. How selective are clinical phosphorylation to inhibit the STING signaling pathway in
CDK4/6 inhibitors? Med Res Rev. 2021;41(3):1578-1598. prostate cancer. Cancer Res. 2024;84(16):2588-2606.
doi: 10.1002/med.21769 doi: 10.1158/0008-5472.CAN-23-3704
13. Pandey K, An HJ, Kim SK, et al. Molecular mechanisms of 24. Zhou C, Zhao S, Zhang Y, Cheng J, Shi J, Du G. Mesoporous
resistance to CDK4/6 inhibitors in breast cancer: A review. polydopamine targeting CDK4/6 inhibitor toward brilliant
Int J Cancer. 2019;145(5):1179-1188. synergistic immunotherapy of breast cancer. Small.
doi: 10.1002/ijc.32020 2024;20(30):e2310565.
14. Mouron S, Bueno MJ, Munoz M, et al. p27Kip1 V109G as doi: 10.1002/smll.202310565
a biomarker for CDK4/6 inhibitors indication in hormone 25. Uzhachenko RV, Bharti V, Ouyang Z, et al. Metabolic
receptor-positive breast cancer. JNCI Cancer Spectr. modulation by CDK4/6 inhibitor promotes chemokine-
2023;7(2):pkad014. mediated recruitment of T cells into mammary tumors. Cell
doi: 10.1093/jncics/pkad014 Rep. 2021;35(12):109271.
15. Hafner M, Mills CE, Subramanian K, et al. Multiomics doi: 10.1016/j.celrep.2021.109271
profiling establishes the polypharmacology of FDA-approved 26. Wang Q, Guldner IH, Golomb SM, et al. Single-cell profiling
CDK4/6 inhibitors and the potential for differential clinical guided combinatorial immunotherapy for fast-evolving
activity. Cell Chem Biol. 2019;26(8):1067-1080.e8. CDK4/6 inhibitor-resistant HER2-positive breast cancer.
doi: 10.1016/j.chembiol.2019.05.005 Nature Commun. 2019;10(1):3817.
16. Zhang Y, Zheng J. Functions of immune checkpoint doi: 10.1038/s41467-019-11729-1
molecules beyond immune evasion. Adv Exp Med Biol. 27. Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6
2020;1248:201-226. inhibitor abemaciclib induces a T cell inflamed tumor
doi: 10.1007/978-981-15-3266-5_9 microenvironment and enhances the efficacy of PD-L1
checkpoint blockade. Cell Rep. 2018;22(11):2978-2994.
17. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: Current researches
in cancer. Am J Cancer Res. 2020;10(3):727-742. doi: 10.1016/j.celrep.2018.02.053
18. Hossen MM, Ma Y, Yin Z, et al. Current understanding 28. Xiao J, Liang J, Fan J, et al. CDK4/6 inhibition enhances
of CTLA-4: From mechanism to autoimmune diseases. oncolytic virus efficacy by potentiating tumor-selective
Frontiers in Immunol. 2023;14:1198365. cell killing and T-cell activation in refractory glioblastoma.
Cancer Res. 2022;82(18):3359-3374.
doi: 10.3389/fimmu.2023.1198365
doi: 10.1158/0008-5472.CAN-21-3656
19. Rosskopf S, Leitner J, Zlabinger GJ, Steinberger P.
CTLA-4 antibody ipilimumab negatively affects CD4 29. Wu J, Wang J, O’Connor TN, et al. Separable cell cycle arrest
+
T-cell responses in vitro. Cancer Immunol Immunother. and immune response elicited through pharmacological
2019;68(8):1359-1368. CDK4/6 and MEK inhibition in RAsmut disease models.
Mol Cancer Ther. 2024;23(12):1801-1814.
doi: 10.1007/s00262-019-02369-x
doi: 10.1158/1535-7163.MCT-24-0369
20. Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition
augments antitumor immunity by enhancing t-cell 30. Zhang Y, Lian Y, Zhou C, et al. Self-assembled natural
activation. Cancer Discov. 2018;8(2):216-233. triterpenoids for the delivery of cyclin-dependent kinase
4/6 inhibitors to enhance cancer chemoimmunotherapy.
doi: 10.1158/2159-8290.CD-17-0915
J Control Release. 2025;378:791-802.
21. Tong J, Tan X, Song X, et al. CDK4/6 inhibition suppresses doi: 10.1016/j.jconrel.2024.12.067
p73 phosphorylation and activates DR5 to potentiate
chemotherapy and immune checkpoint blockade. Cancer 31. Lelliott EJ, Kong IY, Zethoven M, et al. CDK4/6 inhibition
Res. 2022;82(7):1340-1352. promotes antitumor immunity through the induction of
T-cell memory. Cancer Discov. 2021;11(10):2582-2601.
doi: 10.1158/0008-5472.CAN-21-3062
doi: 10.1158/2159-8290.CD-20-1554
22. Wang L, Wu Y, Kang K, et al. CDK4/6 inhibitor abemaciclib
combined with low-dose radiotherapy enhances the anti- 32. Yang WC, Wei MF, Huang CS, Shen YC, Kuo SH. Synergistic
tumor immune response to PD-1 blockade by inflaming potential of CDK4/6 inhibitors and radiotherapy with Anti-
the tumor microenvironment in Rb-deficient small cell lung PD-L1 immunotherapy in triple-negative breast cancer. Int J

Volume 4 Issue 3 (2025) 27 doi: 10.36922/TD025190037